Prolonged Viral Shedding in Cancer Patients with Asymptomatic or Mild Omicron Infection: A Retrospective Study

References

• Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in Southern Africa. Nature. 2022;603(7902):679–686. doi:10.1038/s41586-022-04411-y.
   PubMed Web of Science ®Google Scholar
• Cai J, Deng X, Yang J, et al. Modeling transmission of SARS-CoV-2 Omicron in China. Nat Med. 2022;35537471.doi:10.1038/s41591-022-01855-7
   Web of Science ®Google Scholar
• Zhang X, Zhang W, Chen S. Shanghai’s life-saving efforts against the current omicron wave of the COVID-19 pandemic. Lancet. 2022;399(10340):2011–2012. doi:10.1016/S0140-6736(22)00838-8
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhi H, Teng Y. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. J Med Virol. 2023;95(1):e28138. doi:10.1002/jmv.28138
   PubMed Web of Science ®Google Scholar
• Parsons RJ, Acharya P. Evolution of the SARS-CoV-2 Omicron spike. Cell Rep. 2023;42(12):113444. doi:10.1016/j.celrep.2023.113444
   PubMed Web of Science ®Google Scholar
• Chang MG, Yuan X, Yuan X, et al. Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection. Am J Resp Crit Care. 2020;201(9):1150–1152. doi:10.1164/rccm.202003-0524LE
   PubMed Web of Science ®Google Scholar
• Yang Y, Hu X, Xiong L, et al. Clinical characteristics of hospitalized mild/moderate COVID-19 patients with a prolonged negative conversion time of SARS-CoV-2 nucleic acid detection. Bmc Infect Dis. 2021;21(1):141. doi:10.1186/s12879-021-05851-z
   PubMed Web of Science ®Google Scholar
• Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients. Clin Infect Dis. 2020;71(16):2249–2251. doi:10.1093/cid/ciaa460.
   PubMed Web of Science ®Google Scholar
• Avanzato VA, Matson MJ, Seifert SN, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020;183(7):1901–1912.e9. doi:10.1016/j.cell.2020.10.049
   PubMed Web of Science ®Google Scholar
• Gur I, Giladi A, Isenberg YN, Neuberger A, Stern A. COVID-19 in patients with hematologic malignancies: clinical manifestations, persistence, and immune response. Acta Haematol-Basel. 2022;145(3):297–309. doi:10.1159/000523872
   PubMed Web of Science ®Google Scholar
• Starkey T, Ionescu MC, Tilby M, et al. A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP). Sci Rep-Uk. 2023;13(1):11327. doi:10.1038/s41598-023-36990-9
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China . 关于印发新型冠状病毒肺炎防控方案 (第九版) 的通知 [Notice on Issuing the Novel Coronavirus Pneumonia Prevention and Control Plan (Ninth Edition)]. Available from: http://www.nhc.gov.cn/jkj/s3577/202206/de224e7784fe4007b7189c1f1c9d5e85.shtml. Accessed 18 December 2023.
   Google Scholar
• Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: friend or foe? Life Sci. 2020;256:117900. doi:10.1016/j.lfs.2020.117900
   PubMed Web of Science ®Google Scholar
• Joukar F, Yaghubi KT, Khoshsorour M, et al. Persistence of SARS-CoV-2 RNA in the nasopharyngeal, blood, urine, and stool samples of patients with COVID-19: a hospital-based longitudinal study. Virol J. 2021;18(1):134. doi:10.1186/s12985-021-01599-9
   PubMed Web of Science ®Google Scholar
• Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020;17(3):519–527. doi:10.20892/j.issn.2095-3941.2020.0289
   PubMed Web of Science ®Google Scholar
• Lee L, Starkey T, Ionescu MC, et al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. Lancet Oncol. 2022;23(6):748–757. doi:10.1016/S1470-2045(22)00202-9
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yang Q, Ye J, et al. Clinical features and death risk factors in COVID-19 patients with cancer: a retrospective study. Bmc Infect Dis. 2021;21(1):760. doi:10.1186/s12879-021-06495-9
   PubMed Web of Science ®Google Scholar
• Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):893–903. doi:10.1016/S1470-2045(20)30309-0
   PubMed Web of Science ®Google Scholar
• Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 2021;22(5):581–583. doi:10.1016/S1470-2045(21)00155-8
   PubMed Web of Science ®Google Scholar
• Mandal A, Singh P, Samaddar A, et al. Vaccination of cancer patients against COVID-19: towards the end of a dilemma. Med Oncol. 2021;38(8):92. doi:10.1007/s12032-021-01540-8
   PubMed Web of Science ®Google Scholar
• Wang L, Xu Y, Zhang L, et al. COVID-19 vaccination for cancer patients: progress and preliminary recommendations. Zhongguo Fei Ai Za Zhi. 2021;24(6):377–383. doi:10.3779/j.issn.1009-3419.2021.101.18.
   PubMedGoogle Scholar
• Luo B, Li J, Hou X, et al. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination. Future Oncol. 2021;17(26):3477–3484. doi:10.2217/fon-2021-0288.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. New Engl J Med. 2022;386(23):2188–2200. doi:10.1056/NEJMoa2116620.
   PubMed Web of Science ®Google Scholar
• Stuver R, Shah GL, Korde NS, et al. Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell. 2022;40(6):590–591. doi:10.1016/j.ccell.2022.05.007.
   PubMed Web of Science ®Google Scholar
• Chen B, Haste N, Binkin N, et al. Real world effectiveness of tixagevimab/cilgavimab (evusheld) in the Omicron era. PLoS One. 2023;18(4):e0275356. doi:10.1371/journal.pone.0275356.
   PubMed Web of Science ®Google Scholar
• Zhang J, Cong Y, Duan L, Zhang J. Combined antibodies evusheld against the sars-cov-2 omicron variants ba.1.1 and ba.5: immune escape mechanism from molecular simulation. J Chem Inf Model. 2023;63(16):5297–5308. doi:10.1021/acs.jcim.3c00813.
   PubMedGoogle Scholar
• Zhao Q, Wang X, Zhang Z, et al. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld. J Med Virol. 2023;95(7):e28932. doi:10.1002/jmv.28932
   PubMed Web of Science ®Google Scholar
• Chang A, Koff JL, Lai L, et al. Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies. Blood Adv. 2023;7(11):2459–2462. doi:10.1182/bloodadvances.2022009475
   PubMed Web of Science ®Google Scholar
• Laracy JC, Yan J, Steiger SN, et al. Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients. Haematologica. 2023;108(11):3058–3067. doi:10.3324/haematol.2023.283015.
   PubMed Web of Science ®Google Scholar
• Nanda A, Vura N, Gravenstein S. COVID-19 in older adults. Aging Clin Exp Res. 2020;32(7):1199–1202. doi:10.1007/s40520-020-01581-5
   PubMed Web of Science ®Google Scholar
• Yonekawa A, Shimono N. Clinical significance of covid-19 and diabetes: in the pandemic situation of sars-cov-2 variants including Omicron (B.1.1.529). Biology-Basel. 2022;11(3). doi:10.3390/biology11030400
   Web of Science ®Google Scholar
• Melidis C, Vantsos M. [Comment] Ethical and practical considerations on cancer recommendations duringCOVID-19 pandemic. Mol Clin Oncol. 2020;13(3):5. doi:10.3892/mco.2020.2075
   PubMed Web of Science ®Google Scholar
• Boniface D, Tapia-Rico G. Oncology during the covid-19 pandemic: a lockdown perspective. Curr Oncol Rep. 2022;24(10):1219–1235. doi:10.1007/s11912-022-01301-4.PubMed:
   PubMed Web of Science ®Google Scholar
• Pigozzi E, Tregnago D, Costa L, et al. Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy. PLoS One. 2021;16(3):e0248714. doi:10.1371/journal.pone.0248714
   PubMed Web of Science ®Google Scholar
• Miaskowski C, Paul SM, Snowberg K, et al. Stress and symptom burden in oncology patients during the covid-19 pandemic. J Pain Symptom Manag. 2020;60(5):e25–e34. doi:10.1016/j.jpainsymman.2020.08.037
   PubMed Web of Science ®Google Scholar
• Hesary FB, Salehiniya H. The impact of the covid-19 epidemic on diagnosis, treatment, concerns, problems, and mental health in patients with gastric cancer. J Gastrointest Cancer. 2022;53(3):797–804. doi:10.1007/s12029-021-00692-0
   PubMed Web of Science ®Google Scholar